Christopher A. Klebanoff, MD Extramural Researcher Biography Christopher Klebanoff, MD, is a cellular immunologist and medical oncologist with 17 years of experience in the preclinical and clinical development of T cell-based immunotherapies for the treatment of solid and hematologic cancers. Prior to joining Memorial Sloan Kettering Cancer Center, Dr. Klebanoff was an Assistant Clinical Investigator and an NIH-Howard Hughes Medical Institute Research Scholar at the U.S. National Institutes of Health in Bethesda, Maryland. As a member of the NCI Surgery Branch’s senior staff, he participated in the early phase clinical development of numerous T cell-based therapies that would later be licensed to commercial entities. These include the anti-CD19 28ζ CAR that would become Yescarta; gene-engineered T-cell receptor therapies targeting NY-ESO-1, MAGE-A3/6 and HPV E6; and neoantigen selected tumor-infiltrating lymphocyte therapies for a diverse range of solid cancers. Dr. Klebanoff’s laboratory investigations have contributed to the mechanistic understanding of how lymphodepletion enhances adoptive immunotherapies and how T cell differentiation status influences cellular persistence and clinical outcomes. Education & Training 2000: Emory University, BS, Chemistry 2006: Emory University School of Medicine, MD Awards & Honors 2019: Brain Tumor Funders’ Collaborative Grant 2013: NIH Fellows Award for Research Excellence 2011: NCI/Center for Cancer Research Post Doctoral Research Fellow of the Year 2006: AOA National Medical Honor Society 2004: Howard Hughes Medical Institute continuing support scholarship 2000: Merck Index Award